Value For Italy

By clicking on the menu tabs above, use the map and the interactive sections to discover how AstraZeneca is contributing to the economic growth, research and innovation in Italy

Mappa Italia con regioni

Economic Impact

The added value to the Italian economy


For every euro of added value generated in the last 10 years


an additional €2.56 of value is generated in the Italian economy.


The contribution to the Italian GDP generated by the activities of AstraZeneca in the last 10 years

~ €2bln

of additional contribution to the GDP over the next 3 years, with 25% estimated growth

Mappa Italia con regioni Economy and Work

Occupational Impact

For every new AstraZeneca job


jobs have been created in the Italian economy


jobs have been indirectly created by the launch of partnerships and the implementation of supply chains


jobs activated by 2023 (more than double compared to 2020)

about 800 people are directly employed by AstraZeneca in Italy

Crescita occupati

Employment growth in 5 years

5.6% higher than the industry average
Posti attivabili

GDP growth contribution

308 mln/€ the contribution to the GDP in 2020 (which will take the contribution to 602 milion euros in 2023)
Distribuzione occupazione a livello

Regional distribution of employees

36.3% of the job profiles are in the Centre-South


72% of total employees (about 800)

Gender equity

52% of the managers in the total workforce are women


80% of internships developed into stable employments

Economy and Work

Economic Impact

Over the last 10 years, AstraZeneca operations in Italy have contributed a total of €5.5 billion to the country's GDP (€308 million in 2020 alone, with an expected €602 million in 2023 through an estimated growth of 25% per annum over the next three years)

For every €1 of direct added value generated by AstraZeneca in Italy over the last 10 years (2010-2020), an additional €2.56 was generated throughout the economy, with a significant multiplier effect on the country's economy

Occupational Impact

AstraZeneca activated 3,000 jobs in Italy by 2020, with a multiplier effect on direct employment of 4.18: this means that for every person employed by AstraZeneca in Italy (around 800 throughout the country), a further 3.2 jobs are activated in the country's economy (through the launch of partnerships and the operation of supply chains)

Employment growth is higher than the sector and the private sector average, with an increase in the last 5 years of 5.6% and the forecast to activate 6,000 jobs in Italy by 2023 (more than doubled vs. 2020)

AstraZeneca provides quality employment, recognised by the most important international certifications and located throughout the country, with 36.3% of national roles active in southern regions. In addition, the proportion of graduates in the workforce (72%) is almost 20 percentage points higher than the industry average and more than three times the national average.

AstraZeneca also promotes internships that provide a real opportunity to enter the world of work, resulting, in 80% of cases, in employment with the company at the end of the training course (2020 data).

Female employment at AstraZeneca exceeds benchmarks, particularly in managerial roles, with women exceeding 50% of total employees

Therapeutic Areas

AstraZeneca is actively involved in therapeutic areas that have the greatest impact in terms of mortality, quality of life and cost for the National Health Service:

Research and Development

80 over

Clinical Studies currently launched in Italy

In over


Independent Studies


RWE Studies

1st company in terms of growth as a percentage of the national total for new studies launched

National leader in lung cancer research (22 studies)

2nd company for growth of number of new clinical studies launched

National leader in ovarian cancer research (12 studies)

Support for independent research

21 thousand patients engaged
14 regions involved
70 new studies launched

Investments in clinical research


The benefits generated for the National Health System thanks to economic savings and improved care with new drugs*



100 mln/€

in 2020



200 mln/€

in 2023

€1 invested in Italy in clinical studies

generated an additional €4.23  in benefits for the NHS*

*Source: The European House - Ambrosetti estimation on Altems' research data, 2021

Science and Health


AstraZeneca is one of the leading companies in Italy in terms of its contribution to clinical research in the country (4th overall), with a higher percentage of investment per employee than in the industry as a whole, ranking:
1st company in terms of growth as a percentage of the national total for new studies launched
2nd company for growth of number of new clinical studies launched Current national leader in clinical research for lung and ovarian cancer (with 22 and 12 ongoing studies respectively)

The clinical studies underway in Italy (currently more than 80) are distributed throughout the country, involving more than 200 centres in 10 regions by 2020, allowing over 2000 patients early access to the most innovative drugs.

In addition, through support for independent research, an additional 21,000 patients in 14 Italian regions have been involved, with over 70 new studies activated.

Thanks to investments in clinical research in Italy (€24 million in 2020, a figure expected to double to €48 million by 2023), AstraZeneca has produced benefits for the NHS in terms of economic savings and improved care with new drugs, corresponding to more than €100 million in 2020: according to a study by Altems, every euro invested in Italy in clinical studies has produced an additional €4.23 in benefits for the system (placing AstraZeneca among the pharmaceutical companies with the highest positive leverage effect generated on the NHS)


AstraZeneca contribution to scientific knowledge in Italy is substantiated by the continuous growth in the number of publications it has produced (around 200 in the last 5 years), to such an extent that it is recognised by Italian healthcare professionals as one of the leaders in pharmaceutical science for the quality of its interactions, scientific comparisons and sharing, educational programmes and evidence generation.

AstraZeneca support for training and information activities in Italy has triggered more than 30,000 scientific discussions across the country in the last year, in the last ten years reaching over 75,000 healthcare professionals in different regions and building valuable partnerships with leading Italian universities (4-5 new scientific partnerships are expected to be forged each year until 2023).

Digital Services

The Digital Strategy of AstraZeneca provides for the realization of a series of highly innovative projects and services dedicated to patients, with personalized services and support capable of generating relevant benefits for the NHS

Digitalization areas



AstraZeneca investments in innovation


Patients involved in innovative projects

> 60

centres involved

Open Innovation

A path of innovation shared with public, institutional and private partners

Innovative Hubs

The Federation Model is a district that will enable the acceleration of scientific research. Location: MIND, Milano Innovation District

60 research and innovation centres in which AstraZeneca has already implemented innovative projects and solutions

More than 20 Health Innovation Hubs* in the world bringing together digital, R&D and commercial resources to reimagine how we can improve patient outcomes

Public-private partnerships

that produce value for the system thanks to the integration of skills and different visions (AZ + Tech/ Start-ups + Governments/Health Systems)

Start-up hubs

Incubators and accelerator models for developing innovative solutions through the collaboration of AstraZeneca with many outstanding start-ups

System partnerships

Between AstraZeneca and Governments/Healthcare Systems

Experiential Design Centres

In-house (AstraZeneca Team/Brand) to redefine go-to-market strategies for the company's products, services and experience

External (HCPs/Patients) to study, design and test innovative solutions



AstraZeneca is also managing of digitalization projects at national level. The projects Haya and Ultraspecialist focus on the oncological area.

Haya facilitates the managment of a shared path to care for cancer patients, between doctors and centers, through teleconsultations, telemonitoring and home care solutions. It involves 1000 patients

Ultraspecialists is a teleconsulting platform for patients with ovarian and lung cancer. It involves 70 patients.

Digital Solutions

AstraZeneca is one of the founding companies of "The Federation Model", a district that will be built within MIND, Milano Innovation District, with the aim of creating optimal solutions to accelerate scientific research in our country and innovation in the various dimensions of people's lives. It will do so by bringing together the various innovative digital projects and solutions activated in more than 60 centres, encouraging public-private partnerships in a virtuous system of innovation on a national scale.

AstraZeneca has established more than 20 Health Innovation Hubs globally to promote new models of interaction between medicine, advanced technologies, patients, healthcare professionals and regulators to reimagine healthcare through sustainability and innovation.

Here's where you can find our global hubs

More than 20 Health Innovation Hubs* in the world pool digital resources, research and development and commercial strategies to reinvent ways of improving treatments.

Mappa mondiale Digital Innovation

*The geographical areas pictured in the map are based on AstraZeneca organization structure

AZMINDset project

Start April 2020
Digital round table
with the presidents of the 24 most important national scientific companies with the Human Technopole Foundation

Digitization and telemedicine, fundamental to promote the continuity of care and monitoring of the health conditions of the most fragile people: to date, there is still no coordination at national level for the development of shared projects

Simplification of processes, which will enable easier access to care (e.g. introduction of digital prescriptions ), but requires systematization of the the procedures for accepting patients

Territorial management of the patient / domiciliation of care, which limits the contagion for those patients who need constant care (e.g. oncology) and has imposed the need to rethink socio-assistance routes

Role of the General Practitioner in the management of chronic diseases, always with a view to promoting more local medicine

Other issues related to the role of scientific information, the organization and staging of congresses, to the contribution of pharmaceutical companies to the evolution of the NHS

Environmental Sustainability

The reduction of the environmental impact of its activity represents one of the pillars of the sustainable strategy adopted by AstraZeneca, both in Italy and globally.


Green initiatives currently carried out in Italy


Pillars on which AstraZeneca is basing its sustainability strategy:

Mappa Italia con regioni Ambiente



less tons of Co2 in the atmosphere


Carbon Zero*


Carbon Negative**


*Achieving net-zero emissions by 2025
**Permanently reducing the emissions (including providers and partners) by 2030

The initiatives launched in Italy



Green Car Project Renewing company cars with hybrid and electric cars to reduce emissions



Converting to eco-friendly stationery and purchasing sustainable printers



Target -15% of air travel for business trips



Environmental sustainability culture

Foreste e Verde

Forests and greenery

AZ Forest project Protecting the forest and planting greenery to offset emissions

Raccolta rifiuti

Waste collection

Differentiated management of all products



Social activities for employees Park clean-ups (in collaboration with Legambiente)



ISO 14001 Certification Important milestone for a company without production sites



The reduction of the environmental impact of its activity represents one of the pillars of the sustainable strategy adopted by AstraZeneca globally.


The commitment of the AstraZeneca group and its companies, strongly involved in the social context, is based on a sustainable growth approach as well as on a strong connection between the health of patients, the Group's people and the planet .


The sustainability strategy of AstraZeneca is based on three pillars:

  • Access to healthcare
    • Expanding access to economically sustainable health solutions for treatment and prevention
    • Improvement of the therapeutic path through the development of innovative solutions.
  • Environmental protection and respect
    • Reduction of the environmental impact of company processes and products
    • Reaching the Carbon Zero target in 2025
    • Protection of the environment and its ecosystems
  • Ethics and transparency
    • Maintaining high ethical standards and maximum integrity
    • Conducting business activities with due competence, accuracy, diligence and fairness

Strategic study on impacts and contribution to value creation according to the model of the 4 Capitals of The European House - Ambrosetti. AstraZeneca data, 2021